Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.790 +0.170 (+2.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What 10 Analyst Ratings Have To Say About Sage Therapeutics
Via Benzinga
Why Sage Therapeutics Stock Is Tumbling Today
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today. 
Via The Motley Fool
Expert Ratings for Sage Therapeutics
Via Benzinga
Sage Therapeutics's Earnings Outlook
Via Benzinga
What 5 Analyst Ratings Have To Say About Sage Therapeutics
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger. 
Via Benzinga
Sage Therapeutics to Present at Upcoming May Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Stifel 2023 CNS Days
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Appoints Jessica Federer to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
Via Benzinga
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.